IP Library › Granted Patent US 12,371,464
Granted Patent B2
US 12,371,464 · App. 17/551,701 · Granted Jul 29, 2025

Polypeptides and uses thereof

Inventors: Maria Aleksandra Bednarek (Cambridge, GB); Sivaneswary Genapathy (Cambridge, GB)
Assignee: MedImmune Limited
C07K14/575A61P3/00A61P3/04A61P3/10A61K38/00C07K2319/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,464
App. No.
17/551,701
Granted
Jul 29, 2025
Kind
B2
Abstract

Disclosed are polypeptides which are pramlintide analogues and uses thereof. In particular, the present invention relates to polypeptides of SEQ ID NO 2 which are pramlintide analogues conjugated to half-life extending moieties such as albumin binding moieties and uses thereof.

Claims (31)

1. A polypeptide, or a pharmaceutically acceptable salt thereof, comprising the amino acid sequence selected from the group consisting of:

(SEQ ID NO: 15)

K(γE-C18diacid)K[CNTATC]ATQRLANFLRHSSNN(αMePhe)GP

ILPPTEVGSNTY-amide,

(SEQ ID NO: 16)

K(γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN(αMePhe)GPI

LPPTEVGSNTY-amide,

(SEQ ID NO: 17)

K(O2Oc-O2Oc-γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN 

(αMePhe)GPILPPTEVGSNTY-amide, and

(SEQ ID NO: 18)

K(γE-γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN(αMePhe)

GPILPPTEVGSNTY-amide.

2. The polypeptide, or pharmaceutically acceptable salt thereof, comprising the amino acid sequence

(SEQ ID NO: 15)

K(γE-C18diacid)K[CNTATC]ATQRLANFLRHSSNN(αMePhe)GP

ILPPTEVGSNTY-amide.

3. The polypeptide, or pharmaceutically acceptable salt thereof, comprising the amino acid sequence

(SEQ ID NO: 16)

K(γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN(αMePhe)GPI

LPPTEVGSNTY-amide.

4. The polypeptide, or pharmaceutically acceptable salt thereof, comprising the amino acid sequence

(SEQ ID NO: 17)

K(O2Oc-O2Oc-γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN

(αMePhe)GPILPPTEVGSNTY-amide.

5. The polypeptide, or pharmaceutically acceptable salt thereof, comprising the amino acid sequence

(SEQ ID NO: 18)

K(γE-γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN(αMePhe)

GPILPPTEVGSNTY-amide.

6. A pharmaceutical composition comprising the polypeptide or pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable excipient.

7. A kit comprising the polypeptide or pharmaceutically acceptable salt of claim 1 , optionally further comprising instructions for use.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2022
From: BEDNAREK, MARIA ALEKSANDRA; GENAPATHY, SIVANESWARY
To: MEDIMMUNE LIMITED
Reel/Frame 061715/0642 →
Continuity (2)
Provisional Application 63125996 · Dec 16, 2020
Related Publication 20220204580A1 · Jun 30, 2022
References Cited (14)
US 20100222269A1 · Schaffer · 2010 [cited by examiner]
US 20110105394A1 · Schaffer · 2011 [cited by examiner]
US 20160318987A1 · Revell · 2016 [cited by examiner]
WO 2007104789A2 · 2007 [cited by applicant]
WO 2009034119A1 · 2009 [cited by applicant]
WO 2010046357A1 · 2010 [cited by applicant]
WO 2013059336A1 · 2013 [cited by applicant]
WO 2016083499A1 · 2016 [cited by applicant]
WO 2020225781A1 · 2020 [cited by applicant]
WO WO2022129254A1 · 2022 [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2021/086034, European Patent Office, Netherlands, mailed on May 18, 2022, 16 pages. [cited by applicant]
Kruger, O.F., et al., “Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data,” Drugs 64(13):1419-32, Springer, Germany (Jul. 2004). [cited by applicant]
Pullman, J., et al., “Pramlintide is used in the management of insulin-using patients with type 2 and type 1 diabetes,” Vasc Health Risk Manag 2(3):203-212, Dove Medical Press, United Kingdom (Sep. 2006). [cited by applicant]
Roth, J.D., et al., “GLP-1 Rand amylin agonism in metabolic disease: complementary mechanisms and future opportunities,” Br J Pharmacol 166(1):121-136, British Pharmacological Society, United Kingdom (May 2012). [cited by applicant]